Skip to main content
Erschienen in: Current Infectious Disease Reports 6/2012

01.12.2012 | Transplant and Oncology (MG Ison, Section Editor)

Cytomegalovirus in Solid Organ Transplantation: Epidemiology, Prevention, and Treatment

verfasst von: Elena Beam, Raymund R. Razonable

Erschienen in: Current Infectious Disease Reports | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Cytomegalovirus (CMV) is one of the most important pathogens that infect solid organ transplant recipients. CMV is associated with increased morbidity and mortality in this population as a result of its numerous direct and indirect effects. Prevention strategies consist of preemptive therapy and antiviral prophylaxis, and the choice of which preventive approach to implement should be guided by advantages and drawbacks related to the population being managed. There are differences in the approaches to the laboratory diagnosis and treatment of CMV infection and disease depending on assay availability, clinical presentation, disease severity, and specific transplant populations. In this article, the authors aim to summarize recent publications and updates in the epidemiology, diagnosis, prevention, and treatment of CMV infection in solid organ transplant recipients during the past year, including a brief review of future directions in the field.
Literatur
1.
Zurück zum Zitat Zhang LJ, Hanff P, Rutherford C, Churchill WH, Crumpacker CS. Detection of human cytomegalovirus DNA, RNA, and antibody in normal donor blood. J Infect Dis. 1995;171(4):1002.PubMedCrossRef Zhang LJ, Hanff P, Rutherford C, Churchill WH, Crumpacker CS. Detection of human cytomegalovirus DNA, RNA, and antibody in normal donor blood. J Infect Dis. 1995;171(4):1002.PubMedCrossRef
2.
Zurück zum Zitat Kute VB, Vanikar AV, Shah PR, et al. Post-renal transplant cytomegalovirus infection: study of risk factors. Transplant Proc. 2012;44(3):706.PubMedCrossRef Kute VB, Vanikar AV, Shah PR, et al. Post-renal transplant cytomegalovirus infection: study of risk factors. Transplant Proc. 2012;44(3):706.PubMedCrossRef
3.
Zurück zum Zitat Linares L, Sanclemente G, Cervera C, et al. Influence of cytomegalovirus disease in outcome of solid organ transplant patients. Transplant Proc. 2011;43(6):2145.PubMedCrossRef Linares L, Sanclemente G, Cervera C, et al. Influence of cytomegalovirus disease in outcome of solid organ transplant patients. Transplant Proc. 2011;43(6):2145.PubMedCrossRef
4.
Zurück zum Zitat Kim JM, Kim SJ, Joh JW, et al. Is cytomegalovirus infection dangerous in cytomegalovirus-seropositive recipients after liver transplantation? Liver Transplant: AASLD Int Liver Transplant Soc. 2011;17(4):446. Kim JM, Kim SJ, Joh JW, et al. Is cytomegalovirus infection dangerous in cytomegalovirus-seropositive recipients after liver transplantation? Liver Transplant: AASLD Int Liver Transplant Soc. 2011;17(4):446.
5.
Zurück zum Zitat • Bosch W, Heckman MG, Diehl NN, Shalev JA, Pungpapong S, Hellinger WC. Association of cytomegalovirus infection and disease with death and graft loss after liver transplant in high-risk recipients. Am J Transplant: American Soc Transplant American Soc Transplant Surg. 2011;11(10):2181. A large single-center retrospective study describing the significant association between CMV disease and graft failure and death after liver transplantation. • Bosch W, Heckman MG, Diehl NN, Shalev JA, Pungpapong S, Hellinger WC. Association of cytomegalovirus infection and disease with death and graft loss after liver transplant in high-risk recipients. Am J Transplant: American Soc Transplant American Soc Transplant Surg. 2011;11(10):2181. A large single-center retrospective study describing the significant association between CMV disease and graft failure and death after liver transplantation.
6.
Zurück zum Zitat Parsaik AK, Bhalla T, Dong M, et al. Epidemiology of cytomegalovirus infection after pancreas transplantation. Transplantation. 2011;92(9):1044.PubMed Parsaik AK, Bhalla T, Dong M, et al. Epidemiology of cytomegalovirus infection after pancreas transplantation. Transplantation. 2011;92(9):1044.PubMed
7.
Zurück zum Zitat Cordero E, Casasola C, Ecarma R, Danguilan R. Cytomegalovirus disease in kidney transplant recipients: incidence, clinical profile, and risk factors. Transplant Proc. 2012;44(3):694.PubMedCrossRef Cordero E, Casasola C, Ecarma R, Danguilan R. Cytomegalovirus disease in kidney transplant recipients: incidence, clinical profile, and risk factors. Transplant Proc. 2012;44(3):694.PubMedCrossRef
8.
Zurück zum Zitat Boudreault AA, Xie H, Rakita RM, et al. Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis. Transpl Infect Dis. 2011;13(3):244.PubMedCrossRef Boudreault AA, Xie H, Rakita RM, et al. Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis. Transpl Infect Dis. 2011;13(3):244.PubMedCrossRef
9.
Zurück zum Zitat • Brennan DC, Legendre C, Patel D, et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant. 2011;11(11):2453. A retrospective review of three pooled clinical trials demonstrating the lower risk of CMV infection in patients receiving everolimus, as compared with mycophenolic acid, as part of the immunosuppressive regimen.PubMedCrossRef • Brennan DC, Legendre C, Patel D, et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant. 2011;11(11):2453. A retrospective review of three pooled clinical trials demonstrating the lower risk of CMV infection in patients receiving everolimus, as compared with mycophenolic acid, as part of the immunosuppressive regimen.PubMedCrossRef
10.
Zurück zum Zitat • Kang SH, Abdel-Massih RC, Brown RA, Dierkhising RA, Kremers WK, Razonable RR. Homozygosity for the toll-like receptor 2 R753Q single-nucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation. J Infect Dis. 2012;205(4):639. A novel observation that defects in innate immune response is a risk factor for the development of CMV disease in transplant recipients.PubMedCrossRef • Kang SH, Abdel-Massih RC, Brown RA, Dierkhising RA, Kremers WK, Razonable RR. Homozygosity for the toll-like receptor 2 R753Q single-nucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation. J Infect Dis. 2012;205(4):639. A novel observation that defects in innate immune response is a risk factor for the development of CMV disease in transplant recipients.PubMedCrossRef
11.
Zurück zum Zitat • Lisboa LF, Kumar D, Wilson LE, Humar A. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation. 2012;93(2):195. This study highlights the importance of immunity in the control of CMV infection after transplantation.PubMedCrossRef • Lisboa LF, Kumar D, Wilson LE, Humar A. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation. 2012;93(2):195. This study highlights the importance of immunity in the control of CMV infection after transplantation.PubMedCrossRef
12.
Zurück zum Zitat •• Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. 2010;89(7):779. This article serves as the document of a consensus developed by experts in the management of CMV in solid organ transplant recipients.PubMedCrossRef •• Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. 2010;89(7):779. This article serves as the document of a consensus developed by experts in the management of CMV in solid organ transplant recipients.PubMedCrossRef
13.
Zurück zum Zitat Marchetti S, Santangelo R, Manzara S, D'Onghia S, Fadda G, Cattani P. Comparison of real-time PCR and pp65 antigen assays for monitoring the development of Cytomegalovirus disease in recipients of solid organ and bone marrow transplants. New Microbiol. 2011;34(2):157.PubMed Marchetti S, Santangelo R, Manzara S, D'Onghia S, Fadda G, Cattani P. Comparison of real-time PCR and pp65 antigen assays for monitoring the development of Cytomegalovirus disease in recipients of solid organ and bone marrow transplants. New Microbiol. 2011;34(2):157.PubMed
14.
Zurück zum Zitat Rhee JY, Peck KR, Lee NY, Song JH. Clinical usefulness of plasma quantitative polymerase chain reaction assay: diagnosis of cytomegalovirus infection in kidney transplant recipients. Transplant Proc. 2011;43(7):2624.PubMedCrossRef Rhee JY, Peck KR, Lee NY, Song JH. Clinical usefulness of plasma quantitative polymerase chain reaction assay: diagnosis of cytomegalovirus infection in kidney transplant recipients. Transplant Proc. 2011;43(7):2624.PubMedCrossRef
15.
Zurück zum Zitat Lisboa LF, Asberg A, Kumar D, et al. The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response. Transplantation. 2011;91(2):231.PubMedCrossRef Lisboa LF, Asberg A, Kumar D, et al. The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response. Transplantation. 2011;91(2):231.PubMedCrossRef
16.
Zurück zum Zitat Mori T, Kato J, Yamane A, Aisa Y, Nakazato T, Okamoto S. Comparison of the results of quantitative polymerase chain reaction for cytomegalovirus among laboratories. JPN J Clin Hematol. 2011;52(4):204. Mori T, Kato J, Yamane A, Aisa Y, Nakazato T, Okamoto S. Comparison of the results of quantitative polymerase chain reaction for cytomegalovirus among laboratories. JPN J Clin Hematol. 2011;52(4):204.
17.
Zurück zum Zitat • Hayden RT, Yan X, Wick MT, et al. Factors contributing to variability of quantitative viral PCR results in proficiency testing samples: a multivariate analysis. J Clin Microbiol. 2012;50(2):337. This article highlights the various factors that contribute to the variability in the viral load reporting among clinical laboratories.PubMedCrossRef • Hayden RT, Yan X, Wick MT, et al. Factors contributing to variability of quantitative viral PCR results in proficiency testing samples: a multivariate analysis. J Clin Microbiol. 2012;50(2):337. This article highlights the various factors that contribute to the variability in the viral load reporting among clinical laboratories.PubMedCrossRef
18.
Zurück zum Zitat Pang XL, Fox JD, Fenton JM, Miller GG, Caliendo AM, Preiksaitis JK. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant. 2009;9(2):258.PubMedCrossRef Pang XL, Fox JD, Fenton JM, Miller GG, Caliendo AM, Preiksaitis JK. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant. 2009;9(2):258.PubMedCrossRef
19.
Zurück zum Zitat Clari MA, Munoz-Cobo B, Solano C, et al. Performance of the QuantiFERON-cytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon-producing CD8(+) T-cell response in allogeneic stem cell transplant recipients. Clin Vaccine Immunol. 2012;19(5):791.PubMedCrossRef Clari MA, Munoz-Cobo B, Solano C, et al. Performance of the QuantiFERON-cytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon-producing CD8(+) T-cell response in allogeneic stem cell transplant recipients. Clin Vaccine Immunol. 2012;19(5):791.PubMedCrossRef
20.
Zurück zum Zitat Giulieri S, Manuel O. QuantiFERON(R)-CMV assay for the assessment of cytomegalovirus cell-mediated immunity. Expert Rev Mol Diagn. 2011;11(1):17.PubMedCrossRef Giulieri S, Manuel O. QuantiFERON(R)-CMV assay for the assessment of cytomegalovirus cell-mediated immunity. Expert Rev Mol Diagn. 2011;11(1):17.PubMedCrossRef
21.
Zurück zum Zitat Kalil AC, Mindru C, Florescu DF. Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis. Clin Infect Dis. 2011;52(3):313.PubMedCrossRef Kalil AC, Mindru C, Florescu DF. Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis. Clin Infect Dis. 2011;52(3):313.PubMedCrossRef
22.
Zurück zum Zitat Snydman DR, Limaye AP, Potena L, Zamora MR. Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc. 2011;43(3 Suppl):S1.PubMedCrossRef Snydman DR, Limaye AP, Potena L, Zamora MR. Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc. 2011;43(3 Suppl):S1.PubMedCrossRef
23.
Zurück zum Zitat Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4(4):611.PubMedCrossRef Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4(4):611.PubMedCrossRef
24.
Zurück zum Zitat •• Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010;10(5):1228. This paper describes the outcome of 6 months of antiviral prophylaxis in high-risk CMV D+/R− kdidney recipients and serves as the basis for the recommendation of extending the prophylaxis in this cohort to 6 months.PubMedCrossRef •• Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010;10(5):1228. This paper describes the outcome of 6 months of antiviral prophylaxis in high-risk CMV D+/R− kdidney recipients and serves as the basis for the recommendation of extending the prophylaxis in this cohort to 6 months.PubMedCrossRef
25.
Zurück zum Zitat Humar A, Limaye AP, Blumberg EA, et al. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation. 2010;90(12):1427.PubMedCrossRef Humar A, Limaye AP, Blumberg EA, et al. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation. 2010;90(12):1427.PubMedCrossRef
26.
Zurück zum Zitat • Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med. 2010;152(12):761. A prospective randomized multicenter clinical trial showing that extending CMV prophylaxis in lung transplant patients from 3 to 12 months resulted in significant decrease of development of CMV disease.PubMed • Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med. 2010;152(12):761. A prospective randomized multicenter clinical trial showing that extending CMV prophylaxis in lung transplant patients from 3 to 12 months resulted in significant decrease of development of CMV disease.PubMed
27.
Zurück zum Zitat Finlen Copeland CA, Davis WA, Snyder LD, et al. Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial. J Heart Lung Transplant. 2011;30(9):990.PubMedCrossRef Finlen Copeland CA, Davis WA, Snyder LD, et al. Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial. J Heart Lung Transplant. 2011;30(9):990.PubMedCrossRef
28.
Zurück zum Zitat • Wiita AP, Roubinian N, Khan Y, et al. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis. Transplant infectious disease. 2012. A single-center observational study of planned indefinite valganciclovir prophylaxis in lung transplant recipients showing a 50% rate of discontinuation of prophylaxis mainly due to leukopenia. • Wiita AP, Roubinian N, Khan Y, et al. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis. Transplant infectious disease. 2012. A single-center observational study of planned indefinite valganciclovir prophylaxis in lung transplant recipients showing a 50% rate of discontinuation of prophylaxis mainly due to leukopenia.
29.
Zurück zum Zitat • Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation. 2012;93(1):61. A prospective randomized clinical trial in renal transplant recipients comparing preventive with prophylaxis strategy, with results showing that prophylaxis with valganciclovir significantly reduced that rate of CMV infection and disease.PubMedCrossRef • Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation. 2012;93(1):61. A prospective randomized clinical trial in renal transplant recipients comparing preventive with prophylaxis strategy, with results showing that prophylaxis with valganciclovir significantly reduced that rate of CMV infection and disease.PubMedCrossRef
30.
Zurück zum Zitat Couzi L, Pitard V, Sicard X, et al. Antibody-dependent anti-cytomegalovirus activity of human gammadelta T cells expressing CD16 (FcgammaRIIIa). Blood. 2012;119(6):1418.PubMedCrossRef Couzi L, Pitard V, Sicard X, et al. Antibody-dependent anti-cytomegalovirus activity of human gammadelta T cells expressing CD16 (FcgammaRIIIa). Blood. 2012;119(6):1418.PubMedCrossRef
31.
Zurück zum Zitat Lisboa LF, Preiksaitis JK, Humar A, Kumar D. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients. Transplantation. 2011;92(9):1063.PubMed Lisboa LF, Preiksaitis JK, Humar A, Kumar D. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients. Transplantation. 2011;92(9):1063.PubMed
32.
Zurück zum Zitat Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2007;7(9):2106.PubMedCrossRef Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2007;7(9):2106.PubMedCrossRef
33.
Zurück zum Zitat Helantera I, Lautenschlager I, Koskinen P. The risk of cytomegalovirus recurrence after kidney transplantation. Transpl Int. 2011;24(12):1170.PubMedCrossRef Helantera I, Lautenschlager I, Koskinen P. The risk of cytomegalovirus recurrence after kidney transplantation. Transpl Int. 2011;24(12):1170.PubMedCrossRef
34.
Zurück zum Zitat Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev. 2010;23(4):689.PubMedCrossRef Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev. 2010;23(4):689.PubMedCrossRef
35.
Zurück zum Zitat Myhre HA, Haug Dorenberg D, Kristiansen KI, et al. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. Transplantation. 2011;92(2):217.PubMedCrossRef Myhre HA, Haug Dorenberg D, Kristiansen KI, et al. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. Transplantation. 2011;92(2):217.PubMedCrossRef
36.
Zurück zum Zitat Boivin G, Goyette N, Farhan M, Ives J, Elston R. Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis. J Clin Virol. 2012;53(3). Boivin G, Goyette N, Farhan M, Ives J, Elston R. Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis. J Clin Virol. 2012;53(3).
37.
Zurück zum Zitat Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant. 2011;11(5):1079.PubMedCrossRef Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant. 2011;11(5):1079.PubMedCrossRef
38.
Zurück zum Zitat • Griffiths PD, Stanton A, McCarrell E, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011;377(9773):1256. This study provides promising data regarding the potential clinical utility of a vaccine for the prevention of CMV disease in transplant recipients.PubMedCrossRef • Griffiths PD, Stanton A, McCarrell E, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011;377(9773):1256. This study provides promising data regarding the potential clinical utility of a vaccine for the prevention of CMV disease in transplant recipients.PubMedCrossRef
39.
Zurück zum Zitat Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12(4):290.PubMedCrossRef Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12(4):290.PubMedCrossRef
Metadaten
Titel
Cytomegalovirus in Solid Organ Transplantation: Epidemiology, Prevention, and Treatment
verfasst von
Elena Beam
Raymund R. Razonable
Publikationsdatum
01.12.2012
Verlag
Current Science Inc.
Erschienen in
Current Infectious Disease Reports / Ausgabe 6/2012
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-012-0292-2

Weitere Artikel der Ausgabe 6/2012

Current Infectious Disease Reports 6/2012 Zur Ausgabe

Healthcare-Associated Infections (G Bearman and M Stevens, Section Editors)

Antimicrobial Stewardship as Part of the Infection Prevention Effort

Healthcare-Associated Infections (G Bearman and M Stevens, Section Editors)

Health-Care Worker Vaccination for Influenza: Strategies and Controversies

Healthcare-Associated Infections (G Bearman and M Stevens, Section Editors)

Staphylococcus aureus Bacteriuria: Source, Clinical Relevance, and Management

Healthcare-Associated Infections (G Bearman and M Stevens, Section Editors)

Clostridium difficile: Changing Epidemiology, Treatment and Infection Prevention Measures

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.